ANIX (Anixa Biosciences) Market Cap: $89.65 Mil (As of Jun. 26, 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.64
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Market Cap?

Anixa Biosciences ANIX -2.60% 27 Market Cap is $89.65 Mil as of Jun. 26, 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,431 Biotechnology companies, Anixa Biosciences ranks worse than 53.67% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Anixa Biosciences's share price for the quarter that ended in Apr. 2026 was $3. Anixa Biosciences's Shares Outstanding (EOP) for the quarter that ended in Apr. 2026 was 33.92 Mil. Therefore, Anixa Biosciences's market cap for the quarter that ended in Apr. 2026 was $101.77 Mil.

Anixa Biosciences's quarterly market cap declined from Oct. 2025 ($136.35 Mil) to Jan. 2026 ($101.73 Mil) but then increased from Jan. 2026 ($101.73 Mil) to Apr. 2026 ($101.77 Mil).

Anixa Biosciences's annual market cap increased from Oct. 2023 ($98.42 Mil) to Oct. 2024 ($112.69 Mil) and increased from Oct. 2024 ($112.69 Mil) to Oct. 2025 ($136.35 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anixa Biosciences's Enterprise Value for Today is $74.90 Mil.


Anixa Biosciences  (NAS:ANIX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Anixa Biosciences Market Cap Related Terms


Anixa Biosciences Market Cap Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Market Cap Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 143.34 173.12 98.42 112.69 136.35

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.87 100.44 136.35 101.73 101.77

ANIX vs PYPD, LONA, SGMO: Market Cap Comparison

For the Biotechnology subindustry, Anixa Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Market Cap distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Market Cap falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Anixa Biosciences's Market Cap for the fiscal year that ended in Oct. 2025 is calculated as

Market Cap (A: Oct. 2025 )=Share Price (A: Oct. 2025 )*Shares Outstanding (EOP) (A: Oct. 2025 )
=$4.13*33.014
=$136.35

Anixa Biosciences's Market Cap for the quarter that ended in Apr. 2026 is calculated as

Market Cap (Q: Apr. 2026 )=Share Price (Q: Apr. 2026 )*Shares Outstanding (EOP) (Q: Apr. 2026 )
=$3*33.923
=$101.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $89.65 Mil mean?
Anixa Biosciences (ANIX) has a Market Cap of $89.65 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #768 out of 1431 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Anixa Biosciences' Market Cap too high?
Anixa Biosciences' current Market Cap is $89.65 Mil. The Biotechnology industry median Market Cap is 113.83. Anixa Biosciences' value of $89.65 Mil is 21.2% below this industry median. Based on the distribution chart, Anixa Biosciences ranks #768 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Market Cap compare to PYPD and LONA?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #768 out of 1431 companies for Market Cap. This places Anixa Biosciences in the lower half of its industry. The industry median Market Cap is 113.83. Anixa Biosciences' value of $89.65 Mil is 21.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anixa Biosciences's current Market Cap of $89.65 Mil is 21.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anixa Biosciences and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anixa Biosciences's current Market Cap is $89.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Market Cap of $89.65 Mil. The current Market Cap is $89.65 Mil and 21.2% below the Biotechnology industry median of 113.83. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Market Cap is $89.65 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.64
Price